Circular RNAs(circRNAs)play a critical regulatory role in degenerative diseases;however,their functions and therapeutic applications in intervertebral disc degeneration(IVDD)have not been explored.Here,we identified t...Circular RNAs(circRNAs)play a critical regulatory role in degenerative diseases;however,their functions and therapeutic applications in intervertebral disc degeneration(IVDD)have not been explored.Here,we identified that a novel circATXN1 highly accumulates in aging nucleus pulposus cells(NPCs)accountable for IVDD.CircATXN1 accelerates cellular senescence,disrupts extracellular matrix organization,and inhibits mitochondrial respiration.Mechanistically,circATXN1,regulated by heterogeneous nuclear ribonucleoprotein A2B1-mediated splicing circularization,promotes progerin translocation from the cell nucleus to the cytoplasm and inhibits the expression of insulin-like growth factor 1 receptor(IGF-1R).To demonstrate the therapeutic potential of circATXN1,siRNA targeting the backsplice junction of circATNX1 was screened and delivered by tetrahedral framework nucleic acids(tFNAs)due to their unique compositional and tetrahedral structural features.Our siRNA delivery system demonstrates superior abilities to transfect aging cells,clear intracellular ROS,and enhanced biological safety.Using siRNA–tFNAs to silence circATXN1,aging NPCs exhibit reduced mislocalization of progerin in the cytoplasm and up-regulation of IGF-1R,thereby demonstrating a rejuvenated cellular phenotype and improved mitochondrial function.In vivo,administering an aging cell-adapted siRNA nucleic acid framework delivery system to progerin pathologically expressed premature aging mice(zmpste24^(−/−))can ameliorate the cellular matrix in the nucleus pulposus tissue,effectively delaying IVDD.This study not only identified circATXN1 functioning as a cell senescence promoter in IVDD for the first time,but also successfully demonstrated its therapeutic potential via a tFNA-based siRNA delivery strategy.展开更多
基金supported by the Distinguished Young Scientist Fund of Zhejiang Province(LR23H060001)National Natural Science Foundation of China(Nos.82272480,82372486,82072481,21975217,and 82072465)+1 种基金“Pioneer”and“Leading Goose”R&D Program of Zhejiang(2024C03243)Dynamic Research Enterprise for Multidisciplinary Engineering Sciences(DREMES)at Zhejiang University and the University of Illinois at Urbana-Champaign,funded by Zhejiang University.
文摘Circular RNAs(circRNAs)play a critical regulatory role in degenerative diseases;however,their functions and therapeutic applications in intervertebral disc degeneration(IVDD)have not been explored.Here,we identified that a novel circATXN1 highly accumulates in aging nucleus pulposus cells(NPCs)accountable for IVDD.CircATXN1 accelerates cellular senescence,disrupts extracellular matrix organization,and inhibits mitochondrial respiration.Mechanistically,circATXN1,regulated by heterogeneous nuclear ribonucleoprotein A2B1-mediated splicing circularization,promotes progerin translocation from the cell nucleus to the cytoplasm and inhibits the expression of insulin-like growth factor 1 receptor(IGF-1R).To demonstrate the therapeutic potential of circATXN1,siRNA targeting the backsplice junction of circATNX1 was screened and delivered by tetrahedral framework nucleic acids(tFNAs)due to their unique compositional and tetrahedral structural features.Our siRNA delivery system demonstrates superior abilities to transfect aging cells,clear intracellular ROS,and enhanced biological safety.Using siRNA–tFNAs to silence circATXN1,aging NPCs exhibit reduced mislocalization of progerin in the cytoplasm and up-regulation of IGF-1R,thereby demonstrating a rejuvenated cellular phenotype and improved mitochondrial function.In vivo,administering an aging cell-adapted siRNA nucleic acid framework delivery system to progerin pathologically expressed premature aging mice(zmpste24^(−/−))can ameliorate the cellular matrix in the nucleus pulposus tissue,effectively delaying IVDD.This study not only identified circATXN1 functioning as a cell senescence promoter in IVDD for the first time,but also successfully demonstrated its therapeutic potential via a tFNA-based siRNA delivery strategy.
